DOP2013000223A - Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida. - Google Patents
Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida.Info
- Publication number
- DOP2013000223A DOP2013000223A DO2013000223A DO2013000223A DOP2013000223A DO P2013000223 A DOP2013000223 A DO P2013000223A DO 2013000223 A DO2013000223 A DO 2013000223A DO 2013000223 A DO2013000223 A DO 2013000223A DO P2013000223 A DOP2013000223 A DO P2013000223A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dihydrochloride salt
- cancer
- prophylaxis
- treatment
- dihydroimidazo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Sal de diclorhidrato de 2-amino-N-[7-metoxi-8-(3- morfolin-4-ilpropoxi) -2, 3-dihidroimidazo- [1,2- c] quinazolin-5-il] pirimidin-5-carboxamida de Formula (II) o un tautómero, solvato o hidrato de la misma; - métodos para preparar dicha sal de diclorhidrato; - dicha sal de diclorhidrato para el tratamiento yb profilaxis de una enfermedad; - uso de dicha sal de diclorhidrato para la preparacion de un medicamento para el tratamiento yo profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo yb de angiogénesis, más particularmente para el tratamiento o profilaxis de un cancer, particularmente cancer de pulmon, en particular carcinoma de pulmon a células no pequenas, cancer colorrectal, melanoma, cancer pancreático, carcinoma de hepatocitos, carcinoma de hepatocitos o cancer de mama; - composición farmacéutica que comprende dicha sal de diclorhidrato; y combinación farmacéutica que comprende dicha sal de diclorhidrato en combinacián con uno o más agentes farmacéuticos adicionales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11161111A EP2508525A1 (en) | 2011-04-05 | 2011-04-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000223A true DOP2013000223A (es) | 2013-11-15 |
Family
ID=43984137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000223A DOP2013000223A (es) | 2011-04-05 | 2013-10-04 | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida. |
Country Status (42)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| KR102304108B1 (ko) | 2013-04-08 | 2021-09-23 | 바이엘 파마 악티엔게젤샤프트 | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
| RU2016100892A (ru) | 2013-06-14 | 2017-07-19 | Байер Фарма Акциенгезельшафт | Антитела против tweakr и их применение |
| CN103694319B (zh) * | 2013-12-20 | 2018-02-27 | 深圳翰宇药业股份有限公司 | 一种布舍瑞林的纯化方法 |
| EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978830A1 (en) * | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| MA43840A (fr) * | 2015-03-09 | 2018-11-21 | Bayer Healthcare Pharmaceuticals Inc | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées |
| HUE048111T2 (hu) | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| WO2016162229A1 (en) | 2015-04-10 | 2016-10-13 | Capsugel Belgium N.V. | Abiraterone acetate lipid formulations |
| SG11201806274SA (en) | 2016-02-01 | 2018-08-30 | Bayer Pharma AG | Copanlisib biomarkers |
| SG10202007322PA (en) | 2016-02-01 | 2020-09-29 | Bayer Pharma AG | Copanlisib biomarkers |
| SG11201806515RA (en) | 2016-03-02 | 2018-09-27 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| AU2017376766A1 (en) | 2016-12-14 | 2019-06-06 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
| CA3054249A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
| CA3068324A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| MX2020002633A (es) * | 2017-09-08 | 2020-07-13 | Bayer Consumer Care Ag | Formulaciones de copanlisib. |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
| WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| WO2020078788A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| MX2021004412A (es) * | 2018-10-17 | 2021-07-06 | Sandoz Ag | Cocristales que comprenden levotiroxina y un acido dicarboxilico. |
| CN113260365A (zh) * | 2018-12-27 | 2021-08-13 | 治愈医药社株式会社 | 新型化合物及包含其的用于增强抗癌活性的药学组合物 |
| WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH605550A5 (es) | 1972-06-08 | 1978-09-29 | Research Corp | |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB0021865D0 (en) | 2000-09-06 | 2000-10-18 | Smithkline Beecham Plc | Novel pharmaceutical |
| PL226562B1 (pl) | 2002-09-30 | 2017-08-31 | Bayer Pharmaceuticals Corp | Skondensowane pochodne azolopirymidyn, leki zawierające takie pochodne oraz ich zastosowanie |
| JP4323793B2 (ja) | 2002-12-16 | 2009-09-02 | キヤノン株式会社 | ズームレンズ及びそれを有する光学機器 |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CA2713388C (en) * | 2008-01-14 | 2016-03-29 | William Scott | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| PE20130191A1 (es) | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
| UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| KR102304108B1 (ko) * | 2013-04-08 | 2021-09-23 | 바이엘 파마 악티엔게젤샤프트 | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
| EP3077002B1 (en) | 2013-12-03 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| MA43840A (fr) * | 2015-03-09 | 2018-11-21 | Bayer Healthcare Pharmaceuticals Inc | Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
-
2011
- 2011-04-05 EP EP11161111A patent/EP2508525A1/en not_active Withdrawn
-
2012
- 2012-03-27 JO JO201264A patent/JO2958B1/en active
- 2012-03-28 AR ARP120101036A patent/AR085718A1/es not_active Application Discontinuation
- 2012-03-28 UY UY0001033985A patent/UY33985A/es not_active Application Discontinuation
- 2012-03-29 KR KR1020137028852A patent/KR101937501B1/ko active IP Right Grant
- 2012-03-29 UA UAA201312858A patent/UA111604C2/uk unknown
- 2012-03-29 PT PT127121044T patent/PT2694508E/pt unknown
- 2012-03-29 BR BR112013025549A patent/BR112013025549A2/pt not_active Application Discontinuation
- 2012-03-29 JP JP2014503079A patent/JP5763834B2/ja active Active
- 2012-03-29 ES ES12712104.4T patent/ES2529653T3/es active Active
- 2012-03-29 RS RS20150077A patent/RS53811B1/en unknown
- 2012-03-29 CA CA2832123A patent/CA2832123C/en active Active
- 2012-03-29 ME MEP-2015-16A patent/ME02021B/me unknown
- 2012-03-29 MY MYPI2013701860A patent/MY169452A/en unknown
- 2012-03-29 PE PE2013002186A patent/PE20141038A1/es active IP Right Grant
- 2012-03-29 MX MX2013011583A patent/MX336057B/es unknown
- 2012-03-29 SG SG2013071501A patent/SG193595A1/en unknown
- 2012-03-29 DK DK12712104.4T patent/DK2694508T3/en active
- 2012-03-29 EA EA201391470A patent/EA023646B1/ru not_active IP Right Cessation
- 2012-03-29 AP AP2013007219A patent/AP3709A/en active
- 2012-03-29 AU AU2012238891A patent/AU2012238891B2/en active Active
- 2012-03-29 SI SI201230138T patent/SI2694508T1/sl unknown
- 2012-03-29 CU CUP2013000133A patent/CU24208B1/es active IP Right Grant
- 2012-03-29 CN CN201280027509.4A patent/CN103649091B/zh active Active
- 2012-03-29 MA MA36288A patent/MA35014B1/fr unknown
- 2012-03-29 PL PL12712104T patent/PL2694508T3/pl unknown
- 2012-03-29 US US14/009,599 patent/US10383876B2/en active Active
- 2012-03-29 EP EP12712104.4A patent/EP2694508B1/en active Active
- 2012-03-29 WO PCT/EP2012/055600 patent/WO2012136553A1/en active Application Filing
- 2012-03-30 TW TW101111580A patent/TWI549954B/zh active
- 2012-03-30 TW TW105122778A patent/TWI592158B/zh active
-
2013
- 2013-09-20 ZA ZA2013/07105A patent/ZA201307105B/en unknown
- 2013-09-29 IL IL228561A patent/IL228561A/en active IP Right Grant
- 2013-10-03 TN TNP2013000401A patent/TN2013000401A1/fr unknown
- 2013-10-04 GT GT201300234A patent/GT201300234A/es unknown
- 2013-10-04 CO CO13236625A patent/CO6781534A2/es not_active Application Discontinuation
- 2013-10-04 CL CL2013002870A patent/CL2013002870A1/es unknown
- 2013-10-04 DO DO2013000223A patent/DOP2013000223A/es unknown
- 2013-10-04 CR CR20130511A patent/CR20130511A/es unknown
- 2013-11-04 EC ECSP13013006 patent/ECSP13013006A/es unknown
-
2014
- 2014-09-16 HK HK14109333.1A patent/HK1195907A1/zh unknown
-
2015
- 2015-02-04 HR HRP20150138TT patent/HRP20150138T1/hr unknown
- 2015-02-12 SM SM201500037T patent/SMT201500037B/xx unknown
- 2015-02-19 CY CY20151100174T patent/CY1116231T1/el unknown
- 2015-04-28 JP JP2015091455A patent/JP5826961B2/ja active Active
-
2016
- 2016-01-07 US US14/990,350 patent/US9636344B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000223A (es) | Sales de 2,3-dihidroimidazo[1,2-c]quinazolina substituida. | |
| MX2017004128A (es) | Derivados de diarilurea como inhibidores de quinasa p38. | |
| MX363950B (es) | Derivados de urea utiles como inhibidores de quinasa. | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| IN2014DN11099A (es) | ||
| CL2009000651A1 (es) | Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer. | |
| NZ739339A (en) | Apoptosis signal-regulating kinase inhibitor | |
| PE20171516A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri) | |
| WO2014033447A3 (en) | Diaryl urea derivatives as p38 map kinase inhibitors | |
| BR112012026289A2 (pt) | composto orgânico para uso no tratamento de câncer do fígado | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| EA201492004A1 (ru) | Органические композиции для лечения kras-ассоциированных заболеваний | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| MX2015012896A (es) | Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. | |
| EA201890821A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
| MY158693A (en) | Formulation comprising phenylaminopyrimidine derivative as active agent | |
| CY1117579T1 (el) | Παραγωγα φαινυλιου-γουανiδiνης | |
| MX2013009456A (es) | Compuestos de azufre aromaticos sustituidos y metodos para su uso. | |
| WO2014038881A3 (ko) | 피리돈 유도체를 포함하는 단백질 키나제 억제제 | |
| TH152445A (th) | เกลือ 2,3-ไดไฮโดรอิมิดาโซ[1,2,-c]ควินาโซลีนที่ถูกแทนที่(substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts) | |
| TH165140A (th) | การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส | |
| MY193381A (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |